# Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers

> **NCT03128138** · PHASE1 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 48 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** SPH3127

## Key facts

- **NCT ID:** NCT03128138
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-07-30
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03128138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03128138, "Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03128138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*